Super Drugs (Emerging Industry Overview)

This paper provides an overview of the super drugs industry, primarily in the United States. It covers the increased research and investment into combatting the threat of pandemics, drug-resistant viruses (e.g.

Emerging Industry Overview: Super Drugs

Industry Snapshot

One of the most significant problems facing the health care and scientific communities is the continuous challenge of diseases becoming resistant to the drugs designed to cure them, especially for serious gram-positive infections. In developing count thousands of Americans have died from MRSA.

Millenia Hope, Inc. of Montreal, Quebec, continued its research and development of treatments for malaria and HIV/AIDS. These two major diseases continue to be a worldwide challenge, as resistance to existing drugs increases. Its flagship drug, Malarex/MMH 18, formerly known as Aspidos, has had successful tests in the treatment and prevention of malaria, and the company is continuing with further tests in the pursuit of final approval for consumer usage. Millenia also pursued a patent for its inhibitors of HIV RNase H, none of which have ever advanced to clinical trials. A successful drug that targets HIV RNase H will play a significant role in treating HIV/AIDS patients who have become resistant to current treatments. The market for HIV drugs in the first decade of the 2000s was approximately $6 billion and was estimated to reach $10 billion by 2010. The first successful orally bioavailable drug targeting HIV RNase H could be expected to achieve revenues of $350 million to $500 million per year.

WARC subscribers can sign in to keep reading

Not a subscriber?

WARC helps you to plan, create and deliver more effective marketing

  • Prove your case and back-up your idea

  • Get expert guidance on strategic challenges

  • Tackle current and emerging marketing themes

WARC consistently delivers valuable insights that help to make me look like an expert in front of my colleagues and clients.

Dasha Boryso
Strategy Partner, Fetch

You’re in good company

We work with 80% of Forbes' most valuable brands* and 80% of the world's top top-of-the-class agencies.

* Top 10 brands